Fisher MC, Gurr SJ, Cuomo CA, Blehert DS, Jin H,
Stukenbrock EH, et al. Threats posed by the fungal kingdom to
humans, wildlife, and agriculture. mBio. 2020; 11(3):e00449-20.
2. Global Action Fund for Fungal Infections (GAFFI). Priority
fungal infections, global. action fund fungal infection. Geneva,
Switzerland: Global Action Fund for Fungal Infections; 2020.
3. Rodrigues ML, Nosanchuk JD. Fungal diseases as neglected
pathogens: a wake-up call to public health officials. PLoS Negl
Trop Dis. 2020; 14(2):e0007964.
4. Joint United Nations Programme on HIV/AIDS (UNAIDS).
World AIDS day 2019, Geneva, Switzerland: UNAIDS; 2019.
5. Hoving JC, Brown GD, Gómez BL, Govender NP, Limper AH,
May RC, et al. AIDS-related mycoses: updated progress and
future priorities. Trends Microbiol. 2020; 28(6):425-8.
6. Ashraf N, Kubat RC, Poplin V, Adenis AA, Denning DW,
Wright L, et al. Re-drawing the Maps for Endemic Mycoses.
Mycopathologia. 2020; 185(5):843-65. .
7. Oladele RO, Toriello C, Ogunsola FT, Ayanlowo OO, Foden P,
Fayemiwo AS, et al. Prior subclinical histoplasmosis revealed in
Nigeria using histoplasmin skin testing. PLoS One. 2018;
13(5):e0196224.
8. Oladele RO, Ayanlowo OO, Richardson MD, Denning DW.
Histoplasmosis in Africa: An emerging or a neglected disease?
PLoS Negl Trop Dis. 2018; 12(1):e0006046.
9. Nacher M, Blanchet D, Bongomin F, Chakrabarti A, Couppié P,
Demar M, et al. Histoplasma capsulatum antigen detection tests
as an essential diagnostic tool for patients with advanced HIV
disease in low- and middle-income countries: a systematic
review of diagnostic accuracy studies. PLoS Negl Trop Dis.
2018; 12(10):e0006802.
10. Kwizera R, Bongomin F, Lukande R. Deep fungal infections
diagnosed by histology in Uganda: a 70-year retrospective study.
Med Mycol. 2020; 58(8):1044-52.
11. Queiroz-Telles F, Fahal AH, Falci DR, Caceres DH, Chiller T,
Pasqualotto AC. Neglected endemic mycoses. Lancet Infect Dis.
2017; 17(11):e367-77.
12. Zijlstra EE, van de Sande WWJ, Welsh O, Mahgoub ES,
Goodfellow M, Fahal AH. Mycetoma: a unique neglected
tropical disease. Lancet Infect Dis. 2016; 16(1):100-12.
13. Kwizera R, Bongomin F, Meya DB, Denning DW, Fahal AH,
Lukande R. Mycetoma in Uganda: a neglected tropical disease.
PLoS Negl Trop Dis. 2020; 14(4):e0008240.
14. Badiane AS, Ndiaye M, Diongue K, Diallo MA, Seck MC,
Ndiaye D. Geographical distribution of mycetoma cases in
senegal over a period of 18 years. Mycoses. 2020; 63(3):250-6.
15. van de Sande WW. Global burden of human mycetoma: a
systematic review and meta-analysis. PLoS Negl Trop Dis.
2013; 7(11):e2550.
16. Queiroz-Telles F, de Hoog S, Santos DW, Salgado CG, Vicente
VA, Bonifaz A, et al. Chromoblastomycosis. Clin Microbiol
Rev. 2017; 30(1):233-76.
17. Esterre P, Jahevitra M, Andriantsimahavandy A. Humoral
immune response in chromoblastomycosis during and after
therapy. Clin Diagn Lab Immunol. 2000; 7(3):497-500.
18. Rodrigues AM, Della Terra PP, Gremião ID, Pereira SA,
Orofino-Costa R, de Camargo ZP. The threat of emerging and
re-emerging pathogenic Sporothrix species. Mycopathologia.
2020; 185(5):813-42.
19. Chakrabarti A, Bonifaz A, Gutierrez-Galhardo MC, Mochizuki
T, Li S. Global epidemiology of sporotrichosis. Med Mycol.
2015; 53(1):3-14.
20. Arenas R, Sánchez-Cardenas CD, Ramirez-Hobak L, Ruíz
Arriaga LF, Vega Memije ME. Sporotrichosis: from KOH to
molecular biology. J Fungi (Basel). 2018; 4(2):62.
21. Singh-Moodley A, Ismail H, Perovic O. Molecular diagnostics
in South Africa and challenges in the establishment of a
molecular laboratory in developing countries. J Infect Dev
Ctries. 2020; 14(3):236-43.
22. Vilela R, Mendoza L. Human pathogenic entomophthorales.
Clin Microbiol Rev. 2018; 31(4):e00014-8.
23. Wankhade AB, Patro P, Arora RD, Nagarkar NM. Nasofacial
rhinoentomophthoramycosis: a report of two cases from Central
India. J Oral Maxillofac Pathol. 2020; 24(Suppl 1):S124-7.
24. Hay R, Denning DW, Bonifaz A, Queiroz-Telles F, Beer K,
Bustamante B, et al. The diagnosis of fungal neglected tropical
diseases (Fungal NTDs) and the role of investigation and
laboratory tests: an expert consensus report. Trop Med Infect
Dis. 2019; 4(4):122.
25. Hay RJ. Tinea capitis: current status. Mycopathologia. 2017;
182(1-2):87-93.
26. Nweze EI, Eke IE. Dermatophytes and dermatophytosis in the
eastern and southern parts of Africa. Med Mycol. 2018;
56(1):13-28.
27. Bongomin F, Olum R, Nsenga L, Baluku JB. Burden of tinea
capitis among children in Africa: protocol for a systematic
review and meta-analysis of observational studies, 1990-2020.
BMJ Open. 2020; 10(9):e041230.
28. Araya S, Tesfaye B, Fente D. Epidemiology of dermatophyte
and non-dermatophyte fungi infection in Ethiopia. Clin Cosmet
Investig Dermatol. 2020; 13:291-7.
29. Dhaille F, Dillies AS, Dessirier F, Reygagne P, Diouf M,
Baltazard T, et al. A single typical trichoscopic feature is
predictive of tinea capitis: a prospective multicentre study. Br J
Dermatol. 2019; 181(5):1046-51.
30. Brasileiro A, Campos S, Cabete J, Galhardas C, Lencastre A,
Serrão V. Trichoscopy as an additional tool for the differential
diagnosis of tinea capitis: a prospective clinical study. Br J
Dermatol. 2016; 175(1):208-9.
31. Armstrong-James D, Bicanic T, Brown GD, Hoving JC,
Meintjes G, Nielsen K, et al. AIDS-related mycoses: current
progress in the field and future priorities. Trends Microbiol.
2017; 25(6):428-30.
32. Ellis J, Bangdiwala AS, Cresswell FV, Rhein J, Nuwagira E,
Ssebambulidde K, et al. The changing epidemiology of HIVassociated adult meningitis, Uganda 2015-2017. Open Forum
Infect Dis. 2019; 6(10):ofz419.
33. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP,
Chiller TM, et al. Global burden of disease of HIV-associated
cryptococcal meningitis: an updated analysis. Lancet Infect Dis.
2017; 17(8):873-81.
34. Wasserman S, Engel ME, Griesel R, Mendelson M. Burden of
pneumocystis pneumonia in HIV-infected adults in sub-Saharan
Africa: a systematic review and meta-analysis. BMC Infect Dis.
2016; 16(1):482.
35. Masur H, Michelis MA, Greene JB, Onorato I, Stouwe RA,
Holzman RS, et al. An outbreak of community-acquired
Pneumocystis carinii pneumonia: initial manifestation of cellular
immune dysfunction. N Engl J Med. 1981; 305(24):1431-8.
36. Huang L, Cattamanchi A, Davis JL, den Boon S, Kovacs J,
Meshnick S, et al. HIV-associated Pneumocystis pneumonia.
Proc Am Thorac Soc. 2011; 8(3):294-300.
37. Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC.
Pneumocystis jiroveci pneumonia in immunocompromised
patients: delayed diagnosis and poor outcomes in non-HIVinfected individuals. J Microbiol Immunol Infect. 2014;
47(1):42-7.
38. Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet
A. Combined quantification of pulmonary Pneumocystis
jirovecii DNA and serum (1→ 3)-β-d-glucan for differential
diagnosis of Pneumocystis pneumonia and Pneumocystis
colonization. J Clin Microbiol. 2013; 51(10):3380-8.
39. Alanio A, Hauser PM, Lagrou K, Melchers WJ, Helweg-Larsen
J, Matos O, et al. ECIL guidelines for the diagnosis
of Pneumocystis jirovecii pneumonia in patients with
haematological malignancies and stem cell transplant recipients.
J Antimicrob Chemother. 2016; 71(9):2386-96.
40. Choe PG, Kang YM, Kim G, Park WB, Park SW, Kim HB, et al.
Diagnostic value of direct fluorescence antibody staining for
detecting Pneumocystis jirovecii in expectorated sputum from
patients with HIV infection. Med Mycol. 2014; 52(3):326-30.
41. Nowaseb V, Gaeb E, Fraczek MG, Richardson MD, Denning
DW. Frequency of Pneumocystis jirovecii in sputum from HIV
and TB patients in Namibia. J Infect Dev Ctries. 2014;
8(3):349-57.
42. Samuel CM, Whitelaw A, Corcoran C, Morrow B, Hsiao NY,
Zampoli M, et al. Improved detection of Pneumocystis jirovecii
in upper and lower respiratory tract specimens from children
with suspected pneumocystis pneumonia using real-time PCR: a
prospective study. BMC Infect Dis. 2011; 11:329.
43. Mushi MF, Bader O, Taverne-Ghadwal L, Bii C, Groß U,
Mshana SE. Oral candidiasis among African human
immunodeficiency virus-infected individuals: 10 years of
systematic review and meta-analysis from sub-Saharan Africa. J
Oral Microbiol. 2017; 9(1):1317579.
44. Oladele RO, Denning DW. Burden of serious fungal infection in
Nigeria. West Afr J Med. 2014; 33(2):107-14.
45. Olum R, Baluku JB, Okidi R, Andia-Biraro I, Bongomin F.
Prevalence of HIV-associated esophageal candidiasis in subSaharan Africa: a systematic review and meta-analysis. Trop
Med Health. 2020; 48:82.
46. Loreto ES, Scheid LA, Nogueira CW, Zeni G, Santurio JM,
Alves SH. Candida dubliniensis: epidemiology and phenotypic
methods for identification. Mycopathologia. 2010; 169(6):
431-43.
47. Johnson PC, Sarosi GA, Septimus EJ, Satterwhite TK.
Progressive disseminated histoplasmosis in patients with the
acquired immune deficiency syndrome: a report of 12 cases and
a literature review. Semin Respir Infect. 1986; 1(1):1-8.
48. Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIVinfected patients: a review of new developments and remaining
gaps. Curr Trop Med Rep. 2014; 1(2):119-28.
49. Nacher M, Adenis A, Adriouch L, Dufour J, Papot E, Hanf M, et
al. What is AIDS in the Amazon and the Guianas? Establishing
the burden of disseminated histoplasmosis. Am J Trop Med Hyg.
2011; 84(2):239-40.
50. Daher EF, Silva GB Jr, Barros FA, Takeda CF, Mota RM,
Ferreira MT, et al. Clinical and laboratory features of
disseminated histoplasmosis in HIV patients from Brazil. Trop
Med Int Health. 2007; 12(9):1108-15.
51. Neglected Histoplasmosis in Latin America Group.
Disseminated histoplasmosis in Central and South America, the
invisible elephant: the lethal blind spot of international health
organizations. AIDS. 2016; 30(2):167-70.
52. Richer SM, Smedema ML, Durkin MM, Herman KM, Hage CA,
Fuller D, et al. Improved diagnosis of acute pulmonary
histoplasmosis by combining antigen and antibody detection.
Clin Infect Dis. 2016; 62(7):896-902.
53. Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C.
Histoplasmosis. Infect Dis Clin North Am. 2016; 30(1):207-27.
54. Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F,
et al. Tuberculosis and histoplasmosis among human
immunodeficiency virus-infected patients: a comparative study.
Am J Trop Med Hyg. 2014; 90(2):216-23.
55. Samayoa B, Aguirre L, Bonilla O, Medina N, Lau-Bonilla D,
Mercado D, et al. The diagnostic laboratory hub: a new health
care system reveals the incidence and mortality of tuberculosis,
histoplasmosis, and cryptococcosis of PWH in Guatemala. Open
Forum Infect Dis. 2019; 7(1):ofz534.
56. Bongomin F, Kwizera R, Denning DW. Getting histoplasmosis
on the map of international recommendations for patients with
advanced HIV disease. J Fungi (Basel). 2019; 5(3):80.
57. Ebenye CM. A case of disseminated histoplasmosis detected in
peripheral blood smear staining revealing AIDS at terminal
phase in a female patient from cameroon. Case Rep Med. 2012;
2012:215207.
58. Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M,
McKinsey DS, et al. A multicenter evaluation of tests for
diagnosis of histoplasmosis. Clin Infect Dis. 2011; 53(5):448-54.
59. Richardson MD, Warnock DW. Fungal infection: diagnosis and
management. 4th ed. New Jersey: John Wiley & Sons; 2012.
60. Scheel CM, Samayoa B, Herrera A, Lindsley MD, Benjamin L,
Reed Y, et al. Development and evaluation of an enzyme-linked
immunosorbent assay to detect Histoplasma capsulatum
antigenuria in immunocompromised patients. Clin Vaccine
Immunol. 2009; 16(6):852-8.
61. Cáceres DH, Samayoa BE, Medina NG, Tobón AM, Guzmán
BJ, Mercado D, et al. Multicenter validation of commercial
antigenuria reagents to diagnose progressive disseminated
histoplasmosis in people living with HIV/AIDS in two Latin
American Countries. J Clin Microbiol. 2018; 56(6):e01959-17.
62. Dellière S, Rivero-Menendez O, Gautier C, Garcia-Hermoso D,
Alastruey-Izquierdo A, Alanio A. Emerging mould infections:
get prepared to meet unexpected fungi in your patient. Med
Mycol. 2020; 58(2):156-62.
63. Friedman DZP, Schwartz IS. Emerging fungal infections: new
patients, new patterns, and new pathogens. J Fungi (Basel).
2019; 5(3):67.
64. Khairat SM, Sayed AM, Nabih M, Soliman NS, Hassan YM.
Prevalence of Candida blood stream infections among children
in tertiary care hospital: detection of species and antifungal
susceptibility. Infect Drug Resist. 2019; 12:2409-16.
65. Yapar N. Epidemiology and risk factors for invasive candidiasis.
Ther Clin Risk Manag. 2014; 10:95-105.
Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly
emerging cause of hospital-acquired multidrug-resistant fungal
infections globally. PLoS Pathog. 2017; 13(5):e1006290.
67. Lone SA, Ahmad A. Candida auris-the growing menace to
global health. Mycoses. 2019; 62(8):620-37.
68. Magobo RE, Corcoran C, Seetharam S, Govender NP. Candida
auris-associated candidemia, South Africa. Emerg Infect Dis.
2014; 20(7):1250-1.
69. Ademe M, Girma F. Candida auris: From multidrug resistance
to pan-resistant strains. Infect Drug Resist. 2020; 13:1287-94.
70. Sarma S, Upadhyay S. Current perspective on emergence,
diagnosis and drug resistance in Candida auris. Infect Drug
Resist. 2017; 10:155-65.
71. Maphanga TG, Birkhead M, Muñoz JF, Allam M, Zulu TG,
Cuomo CA, et al. Human blastomycosis in South Africa caused
by Blastomyces percursus and Blastomyces emzantsi sp. nov.,
1967 to 2014. J Clin Microbiol. 2020; 58(3):e01661-19.
72. Dukik K, Muñoz JF, Jiang Y, Feng P, Sigler L, Stielow JB, et al.
Novel taxa of thermally dimorphic systemic pathogens in the
Ajellomycetaceae (Onygenales). Mycoses. 2017; 60(5):296-309.
73. Gast KB, van der Hoeven A, de Boer MGJ, van Esser JWJ,
Kuijper EJ, Verweij JJ, et al. Two cases of Emergomyces
pasteurianus infection in immunocompromised patients in the
Netherlands. Med Mycol Case Rep. 2019; 24:5-8.
74. Schwartz IS, Sanche S, Wiederhold NP, Patterson TF, Sigler L.
Emergomyces canadensis, a dimorphic fungus causing fatal
systemic human disease in North America. Emerg Infect Dis.
2018; 24(4):758-61.
75. Schwartz IS, Govender NP, Corcoran C, Dlamini S, Prozesky H,
Burton R, et al. Clinical characteristics, diagnosis, management,
and outcomes of disseminated emmonsiosis: a retrospective case
series. Clin Infect Dis. 2015; 61(6):1004-12.
76. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F,
Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis:
rationale and clinical guidelines for diagnosis and management.
Eur Respir J. 2016; 47(1):45-68.
77. Smith NL, Denning DW. Underlying conditions in chronic
pulmonary aspergillosis including simple aspergilloma. Eur
Respir J. 2011; 37(4):865-72.
78. Oladele RO, Irurhe NK, Foden P, Akanmu AS, Gbaja-Biamila
T, Nwosu A, et al. Chronic pulmonary aspergillosis as a cause of
smear-negative TB and/or TB treatment failure in Nigerians. Int
J Tuberc Lung Dis. 2017; 21(9):1056-61.
79. Page ID, Byanyima R, Hosmane S, Onyachi N, Opira C,
Richardson M, et al. Chronic pulmonary aspergillosis commonly
complicates treated pulmonary tuberculosis with residual
cavitation. Eur Respir J. 2019; 53(3):1801184.
80. Mortezaee V, Mahdaviani SA, Mirenayat MS, Pourabdollah M,
Hassanzad M, Mehrian P, et al. The complications of
Aspergillus fumigatus sensitization in patients with asthma.
Jundishapur J Microbiol. 2020; 13:e99833.
81. Muldoon EG, Strek ME, Patterson KC. Allergic and noninvasive
infectious pulmonary aspergillosis syndromes. Clin Chest Med.
2017; 38(3):521-34.
82. Kwizera R, Musaazi J, Meya DB, Worodria W, Bwanga F,
Kajumbula H, et al. Burden of fungal asthma in Africa: a
systematic review and meta-analysis. PLoS One. 2019;
14(5):e0216568.
83. Geiger AM, Foxman B. Risk factors for vulvovaginal
candidiasis: a case-control study among university students.
Epidemiology. 1996; 7(2):182-7.
84. Sobel JD. Vulvovaginal candidosis. Lancet. 2007; 369(9577):
1961-71.
85. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J,
Silva S. Vulvovaginal candidiasis: epidemiology, microbiology
and risk factors. Crit Rev Microbiol. 2016; 42(6):905-27.
86. Brown SE, Schwartz JA, Robinson CK, OʼHanlon DE, Bradford
LL, He X, et al. The vaginal microbiota and behavioral factors
associated with genital Candida albicans detection in
reproductive-age women. Sex Transm Dis. 2019; 46(11):753-8.
87. Dunaiski CM, Denning DW. Estimated burden of fungal
infections in Namibia. J Fungi (Basel). 2019; 5(3):75.
88. Tufa TB, Denning DW. The burden of fungal infections in
Ethiopia. J Fungi (Basel). 2019; 5(4):109.
89. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R.
Global burden of recurrent vulvovaginal candidiasis: a
systematic review. Lancet Infect Dis. 2018; 18(11):e339-47.
)
